Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;360:1-8.
2. Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381:2440-2450.
3. Garvey WT. Is obesity or adiposity-based chronic disease curable: the set point theory, the environment, and second-generation medications. Endocr Pract. 2022;28(2):214-222.
4. Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an Endocrine Society scientific statement. Endocr Rev. 2018;39(2):79-132.
5. Tahrani AA, Morton J. Benefits of weight loss of 10% or more in patients with overweight or obesity: a review. Obesity (Silver Spring). 2022;30(4):802-840.
7. Schwartz MW, Seeley RJ, Zeltser LM, et al. Obesity pathogenesis: an Endocrine Society scientific statement. Endocr Rev. 2017;38(4):267-296.
8. Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: pathophysiology and management. J Am Coll Cardiol. 2018;71(1):69-84.
9. Alamuddin N, Wadden TA. Behavioral treatment of the patient with obesity. Endocrinol Metab Clin North Am. 2016;45(3):565-580.
10. Lund J, Clemmensen C. Physiological protection against weight gain: evidence from overfeeding studies and future directions. Philos Trans R Soc Lond B Biol Sci. 2023;378:20220229.
11. Pucci A, Batterham RL. Mechanisms underlying the weight loss effects of RYGB and SG: similar, yet different. J Endocrinol Invest. 2019;42(2):117-128.
12. Pontzer H. Energy constraint as a novel mechanism linking exercise and health. Physiology (Bethesda). 2018;33(6):384-393.
13. Grannell A. Reframing the need for exercise therapy in the clinical management of people living with obesity. Clin Obes. 2022;12(6):e12554.
14. Craig HC, Doran ZM, le Roux CW. The concept of healthy behaviours in obesity may have unintended consequences. Nutrients. 2022;15(1):12.
15. Fitch A, Ingersoll AB. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers. Postgrad Med. 2021;133(3):310-319.
16. Mozaffarian D. Perspective: obesity—an unexplained epidemic. Am J Clin Nutr. 2022;115(6):1445-1450.
17. Amato AA, Wheeler HB, Blumberg B. Obesity and endocrine-disrupting chemicals. Endocr Connect. 2021;10(2):R87-R105.
18. Bays HE, Golden A, Tondt J. Thirty obesity myths, misunderstandings, and/or oversimplifications: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS), 2022. Obes Pillars. 2022;3:100034.
19. Garvey WT, Mechanick JI. Proposal for a scientifically correct and medically actionable disease classification system (ICD) for obesity. Obesity (Silver Spring). 2020;28(3):484-492.
20. Bays HE, Burridge K, Richards J, Fitch A. Obesity Pillars roundtable: excessive weight reduction with highly effective anti-obesity medications (heAOMs). Obes Pillars. 2022;4:100039.
21. Ahn YJ, Taormina JM, Tchang BG, Srivastava G, Schmidt SL, Kaplan LM. Letter to the editor of obesity pillars from the Obesity Medicine Fellowship Council. Obesity Pillars. 2023;6:100068.
22. Haam JH, Kim BT, Kim EM, et al. Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity. J Obes Metab Syndr. 2023;32(2):121-129.
23. Hagan S, Nelson K. Are current guidelines perpetuating weight stigma? A weight-skeptical approach to the care of patients with obesity. J Gen Intern Med. 2023;38(3):793-798.
24. Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640.
25. Blüher M, Aras M, Aronne LJ, et al. New insights into the treatment of obesity. Diabetes Obes Metab. 2023;1-15.
26. Weir CB, Jan A. BMI classification percentile and cut off points. StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
27. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract. 2012;18(5):642-648.
29. Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes Pillars. 2022;1:100004.
30. Bays HE, Fitch A, Christensen S, Burridge K, Tondt J. Anti-obesity medications and investigational agents: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obes Pillars. 2022;2:100018.
31. National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Available at https://www.ncbi.nlm.nih.gov/books/NBK2003. Last accessed November 16, 2023.
32. Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15(4):6184-6223.
33. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005;81(3):555-563.
34. Bray GA, Jablonski KA, Fujimoto WY, et al. Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am J Clin Nutr. 2008;87(5):1212-1218.
35. Berg S. AMA: Use of BMI Alone is an Imperfect Clinical Measure. Available at https://www.ama-assn.org/delivering-care/public-health/ama-use-bmi-alone-imperfect-clinical-measure. Last accessed November 16, 2023.
36. Cohen E, Cragg M, deFonseka J, Hite A, Rosenberg M, Zhou B. Statistical review of U.S. macronutrient consumption data, 1965–2011: Americans have been following dietary guidelines, coincident with the rise in obesity. Nutrition. 2015;31(5):727-732.
37. Shan Z, Rehm CD, Rogers G, et al. Trends in dietary carbohydrate, protein, and fat intake and diet quality among U.S. adults, 1999–2016. JAMA. 2019;322(12):1178-1187.
38. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217.
39. Brown RE, Sharma AM, Ardern CI, Mirdamadi P, Mirdamadi P, Kuk JL. Secular differences in the association between caloric intake, macronutrient intake, and physical activity with obesity. Obes Res Clin Pract. 2016;10(3):243-255.
40. Inoue Y, Qin B, Poti J, Sokol R, Gordon-Larsen P. Epidemiology of obesity in adults: latest trends. Curr Obes Rep. 2018;7(4):276-288.
41. Fryar CD, Carroll MD, Afful J, Division of Health and Nutrition Examination Surveys. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018.NCHS Health E-Stats. 2020.
42. Fryar CD, Carroll MD, Afful J, Division of Health and Nutrition Examination Surveys. Prevalence of overweight, obesity, and severe obesity among children and adolescents aged 2–19 years: United States, 1963–1965 through 2017–2018.NCHS Health E-Stats. 2020.
43. Centers for Disease Control and Prevention. Adult Obesity Facts. Available at https://www.cdc.gov/obesity/data/adult.html. Last accessed November 10, 2023.
44. Webber BJ, Bornstein DB, Deuster PA, et al. BMI and physical activity, military-aged U.S. population 2015–2020.Am J Prev Med. 2023;64(1):66-75.
45. Nielsen J, Narayan KV, Cunningham SA. Incidence of obesity across adulthood in the United States, 2001–2017: a national prospective analysis.Am J Clin Nutr. 2023;117(1):141-148.
46. Massie DC, Amaro A, Kaplan M. Patient well-being and the clinical and economic burdens associated with obesity in the United States.Am J Manag Care. 2022;28(15 Suppl):S279-S287.
47. Patel AV, Patel KS, Teras LR. Excess body fatness and cancer risk: a summary of the epidemiologic evidence.Surg Obes Relat Dis. 2023;19(7):742-745.
48. Lustig RH, Collier D, Kassotis C, et al. Obesity I: overview and molecular and biochemical mechanisms.Biochem Pharmacol. 2022;199:115012.
49. Hachuła M, Kosowski M, Zielańska K, Basiak M, OkopieńB. The impact of various methods of obesity treatment on the quality of life and mental health—a narrative review.Int J Environ Res Public Health. 2023;20(3):2122
50. Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex.PLoS One. 2021;16(3):e0247307.
51. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis.JAMA. 2013;309(1):71-82.
52. Doehner W, Clark A, Anker SD. The obesity paradox: weighing the benefit.Eur Heart J. 2010;31(2):146-148.
53. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju S, et al. Body mass index and all-cause mortality: individual participant data meta-analysis of 239 prospective studies in four continents.Lancet. 2016;388(10046):776-786.
54. Fischer NM, Pallazola VA, Xun H, Cainzos-Achirica M, Michos ED. The evolution of the heart-healthy diet for vascular health: a walk through time.Vasc Med. 2020;25(2):184-193.
56. Mozaffarian D, Rosenberg I, Uauy R. History of modern nutrition science: implications for current research, dietary guidelines, and food policy.BMJ. 2018;361:k2392.
57. Lee JH, Duster M, Roberts T, Devinsky O. United States dietary trends since 1800: lack of association between saturated fatty acid consumption and non-communicable diseases.Front Nutr. 2022;8:748847.
58. Ramsden CE, Zamora D, Majchrzak-Hong S, et al. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73).BMJ. 2016;353:i1246.
59. Marantz PR, Bird ED, Alderman MH. A call for higher standards of evidence for dietary guidelines.Am J Prev Med. 2008;34(3):234-240.
60. Achterberg C, Astrup A, Bier DM, et al. An analysis of the recent US dietary guidelines process in light of its federal mandate and a National Academies report.PNAS Nexus. 2022;1(3):1-12.
61. American Diabetes Association, Bantle JP, Wylie-Rosett J, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;31(Suppl 1):S61-S78.
62. Maselli DB, Hoff AC, Kucera A, et al. Endoscopic sleeve gastroplasty in class III obesity: efficacy, safety, and durability outcomes in 404 consecutive patients. World J Gastrointest Endosc. 2023;15(6):469-479.
63. Mayes CR, Thompson DB. What should we eat? Biopolitics, ethics, and nutritional scientism. J Bioeth Inq. 2015;12(4):587-599.
64. Martin CB, Herrick KA, Sarafrazi N, Ogden CL. Attempts to lose weight among adults in the United States, 2013–2016. NCHS Data Brief. 2018;(313):1-8.
65. Gaesser GA, Angadi SS. Obesity treatment: weight loss versus increasing fitness and physical activity for reducing health risks. iScience. 2021;24(10):102995.
66. Carneiro IP, Elliott SA, Siervo M, et al. Is obesity associated with altered energy expenditure? Adv Nutr. 2016;7(3):476-487.
67. Speakman JR, Pontzer H, Rood J, et al. The International Atomic Energy Agency international doubly-labelled water database: aims, scope and procedures. Ann Nutr Metab. 2019;75(2):114-118.
68. Westerterp KR, Speakman JR. Physical activity energy expenditure has not declined since the 1980s and matches energy expenditure of wild mammals. Int J Obes (Lond). 2008;32(8):1256-1263.
69. Lund J, Lund C, Morville T, Clemmensen C. The unidentified hormonal defense against weight gain. PLoS Biol. 2020;18(2):e3000629.
70. Westerterp KR. Control of energy expenditure in humans. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds). Endotext. South Dartmouth, MA: MDText.com, Inc.; 2022.
71. Westerterp KR. Exercise, energy balance and body composition. Eur J Clin Nutr. 2018;72(9):1246-1250.
72. Careau V, Halsey LG, Pontzer H, et al. Energy compensation and adiposity in humans. Curr Biol. 2021;31(20):4659-4666.
73. International Atomic Energy Agency. Press Release: New IAEA Database to Help Countries Tackle Growing Obesity Crisis. December 12, 2018. Available at https://www.iaea.org/newscenter/pressreleases/new-iaea-database-to-help-countries-tackle-growing-obesity-crisis. Last accessed November 14, 2023.
74. Platonova M, Alford A. Obesity Epidemic: IAEA Database Shows How Daily Energy Expenditure Has Changed Over Time. May 18, 2023. Available at https://www.iaea.org/newscenter/news/obesity-epidemic-iaea-database-shows-how-daily-energy-expenditure-has-changed-over-time. Last accessed November 14, 2023.
75. Pontzer H, Durazo-Arvizu R, Dugas LR, et al. Constrained total energy expenditure and metabolic adaptation to physical activity in adult humans. Curr Biol. 2016;26(3):410-417.
76. Hall KD, Heymsfield SB, Kemnitz JW, Klein S, Schoeller DA, Speakman JR. Energy balance and its components: implications for body weight regulation. Am J Clin Nutr. 2012;95(4):989-994.
77. Heindel JJ, Blumberg B. Environmental obesogens: mechanisms and controversies. Annu Rev Pharmacol Toxicol. 2019;59:89-106.
79. Hu S, Zhang X, Stamatiou M, et al. Higher than predicted resting energy expenditure and lower physical activity in healthy underweight Chinese adults. Cell Metab. 2022;34(10):1413-1415.
80. Speakman JR, de Jong JMA, Sinha S, et al. Total daily energy expenditure has declined over the last 3 decades due to declining basal expenditure not reduced activity expenditure. Nat Metab. 2023;5(4):579-588.
81. Cutler DM, Glaeser EL, Shapiro JM. Why have Americans become more obese? J Econ Perspect. 2003;17(3):93-118.
82. Hall KD, Farooqi IS, Friedman JM, et al. The energy balance model of obesity: beyond calories in, calories out. Am J Clin Nutr. 2022;115(5):1243-1254.
83. NCD Risk Factor Collaboration (NCD-RisC). Rising rural body-mass index is the main driver of the global obesity epidemic in adults. Nature. 2019;569(7755):260-264.
84. Datar A, Nicosia N. Assessing social contagion in body mass index, overweight, and obesity using a natural experiment. JAMA Pediatr. 2018;172(3):239-246.
85. Epstein LH, Wen X. Relevance of social networks for adolescent obesity. JAMA Pediatr. 2018;172(3):223-224.
86. Hales CM, Gu Q, Ogden CL, Yanovski SZ. Use of prescription medications associated with weight gain among U.S. adults, 1999–2018: a nationally representative survey. Obesity (Silver Spring). 2022;30(1):229-239.
87. Verhaegen AA, Van Gaal LF. Drugs that affect body weight, body fat distribution, and metabolism. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds). Endotext. South Dartmouth, MA: MDText.com, Inc.; 2019.
88. Tammi R, Männistö S, Harald K, et al. Different carbohydrate exposures and weight gain-results from a pooled analysis of three population-based studies. Int J Obes (Lond). 2023;47(8):743-749.
89. Yan RR, Chan CB, Louie JCY. Current WHO recommendation to reduce free sugar intake from all sources to below 10% of daily energy intake for supporting overall health is not well supported by available evidence. Am J Clin Nutr. 2022;116(1):15-39.
90. Semnani-Azad Z, Khan TA, Mejia SB, et al. Association of major food sources of fructose-containing sugars with incident metabolic syndrome: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(7):e209993.
91. Sundborn G, Thornley S, Merriman TR, et al. Are liquid sugars different from solid sugar in their ability to cause metabolic syndrome? Obesity (Silver Spring). 2019;27(6):879-887.
92. Angelidi AM, Belanger MJ, Kokkinos A, Koliaki CC, Mantzoros CS. Novel noninvasive approaches to the treatment of obesity: from pharmacotherapy to gene therapy. Endocr Rev. 2022;43(3):507-557.
93. Klimentidis YC, Beasley TM, Lin HY, et al. Canaries in the coal mine: a cross-species analysis of the plurality of obesity epidemics. Proc Biol Sci. 2011;278(1712):1626-1632.
94. Loftus JP, Wakshlag JJ. Canine and feline obesity: a review of pathophysiology, epidemiology, and clinical management. Vet Med (Auckl). 2015;6:49-60.
95. Holst BS, Gustavsson MH. Animal obesity: causes, consequences and comparative aspects. Acta Vet Scand. 2016;58(Suppl 1):56.
96. Heindel JJ, Howard S, Agay-Shay K, et al. Obesity II: establishing causal links between chemical exposures and obesity. Biochem Pharmacol. 2022;199:115015.
97. Janesick AS, Blumberg B. Obesogens: an emerging threat to public health. Am J Obstet Gynecol. 2016;214(5):559-565.
98. Landrigan PJ, Raps H, Cropper M, et al. The Minderoo-Monaco Commission on Plastics and Human Health. Ann Glob Health. 2023;89(1):23.
99. Gore AC, Chappell VA, Fenton SE, et al. EDC-2: the Endocrine Society's second scientific statement on endocrine-disrupting chemicals. Endocr Rev. 2015;36(6):E1-E150.
100. Corkey BE. Reactive oxygen species: role in obesity and mitochondrial energy efficiency. Philos Trans R Soc Lond B Biol Sci. 2023;378(1885):20220210.
101. Pucci A, Batterham RL. Endocrinology of the gut and the regulation of body weight and metabolism. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds). Endotext. South Dartmouth, MA: MDText.com, Inc.; 2020.
102. Affinati AH, Myers MG Jr. Neuroendocrine control of body energy homeostasis. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds). Endotext. South Dartmouth, MA: MDText.com, Inc.; 2021.
103. Watts AG, Kanoski SE, Sanchez-Watts G, Langhans W. The physiological control of eating: signals, neurons, and networks. Physiol Rev. 2022;102(2):689-813.
104. Liu CM, Kanoski SE. Homeostatic and non-homeostatic controls of feeding behavior: distinct vs. common neural systems. Physiol Behav. 2018;193(Pt B):223-231.
105. Rimbach R, Yamada Y, Sagayama H, et al. Total energy expenditure is repeatable in adults but not associated with short-term changes in body composition. Nat Commun. 2022;13(1):99.
106. Melanson EL, Keadle SK, Donnelly JE, Braun B, King NA. Resistance to exercise-induced weight loss: compensatory behavioral adaptations. Med Sci Sports Exerc. 2013;45(8):1600-1609.
107. Ylli D, Sidhu S, Parikh T, Burman KD. Endocrine changes in obesity. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds). Endotext. South Dartmouth, MA: MDText.com, Inc.; 2022.
108. MacLean PS, Bergouignan A, Cornier MA, Jackman MR. Biology's response to dieting: the impetus for weight regain. Am J Physiol Regul Integr Comp Physiol. 2011;301(3):R581-R600.
109. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332(10):621-628.
110. Pasquet P, Apfelbaum M. Recovery of initial body weight and composition after long-term massive overfeeding in men. Am J Clin Nutr. 1994;60(6):861-863.
111. Diaz EO, Prentice AM, Goldberg GR, Murgatroyd PR, Coward WA. Metabolic response to experimental overfeeding in lean and overweight healthy volunteers. Am J Clin Nutr. 1992;56(4):641-655.
112. Elliot DL, Goldberg L, Kuehl KS, Bennett WM. Sustained depression of the resting metabolic rate after massive weight loss. Am J Clin Nutr. 1989;49(1):93-96.
113. Leibel RL, Hirsch J. Diminished energy requirements in reduced-obese patients. Metabolism. 1984;33(2):164-170.
114. Sims EA, Goldman RF, Gluck CM, Horton ES, Kelleher PC, Rowe DW. Experimental obesity in man. Trans Assoc Am Physicians. 1968;81:153-170.
115. Narayanaswami V, Dwoskin LP. Obesity: current and potential pharmacotherapeutics and targets. Pharmacol Ther. 2017;170:116-147.
116. Lazarus E, Ortiz-Pujols S. Increasing clinical awareness of obesity as a serious, chronic, relapsing, and treatable disease. Am J Manag Care. 2022;28(15 Suppl):S271-S278.
117. Busetto L, Bettini S, Makaronidis J, Roberts CA, Halford JCG, Batterham RL. Mechanisms of weight regain. Eur J Intern Med. 2021;93:3-7.
118. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25_Part_B):2985-3023.
119. Cornier MA. A review of current guidelines for the treatment of obesity. Am J Manag Care. 2022;28(15 Suppl):S288-S296.
120. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.
121. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.Endocr Pract. 2016;22 Suppl 3:1-203.
122. Fitch A, Alexander L, Brown CF, Bays HE. Comprehensive care for patients with obesity: an Obesity Medicine Association position statement.Obesity Pillars. 2023;7:100070.
123. Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity.Gastroenterology. 2022;163(5):1198-1225.
124. Vosburg RW, El Chaar M, El Djouzi S, et al. Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee.Surg Obes Relat Dis. 2022;18(9):1109-1119.
125. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic and Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists.Surg Obes Relat Dis. 2020;16(2):175-247.
126. Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery.Obes Surg. 2023;33(1):3-14.
127. Shetye B, Hamilton FR, Bays HE. Bariatric surgery, gastrointestinal hormones, and the microbiome: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS), 2022.Obes Pillars. 2022;2:100015.
128. Bays HE, Bindlish S, Clayton TL. Obesity, diabetes mellitus, and cardiometabolic risk: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023.Obes Pillars. 2023;5:100056.
129. van Veldhuisen SL, Gorter TM, van Woerden G, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.Eur Heart J. 2022;43(20):1955-1969.
130. Aminian A, Wilson R, Al-Kurd A, et al. Association of bariatric surgery with cancer risk and mortality in adults with obesity.JAMA. 2022;327(24):2423-2433.
131. Enright C, Thomas E, Saxon DR. An updated approach to antiobesity pharmacotherapy: moving beyond the 5% weight loss goal.J Endocr Soc. 2023;7(3):bvac195.
132. Möller F, Hedberg J, Skogar M, Sundbom M. Long-term follow-up 15 years after duodenal switch or gastric bypass for super obesity: a randomized controlled trial.Obes Surg. 2023;33(10):2981-2990.
133. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity.N Engl J Med. 2022;387(3):205-216.
134. Singh N, Stewart RAH, Benatar JR. Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials.BMJ Open. 2019;9:e029966.
135. Tirthani E, Quartuccio M. Non-dieting approaches to treatment of obesity.StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
136. Coulter AA, Rebello CJ, Greenway FL. Centrally acting drugs for obesity: past, present, and future.Drugs. 2018;78(11):1113-1132.
137. Drugs.com. Semaglutide (Monograph). Available at https://www.drugs.com/monograph/semaglutide.html. Last accessed November 10, 2023.
138. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity.N Engl J Med. 2021;384(11):989-1002.
139. Jeon E, Lee KY, Kim KK. Approved anti-obesity medications in 2022 KSSO guidelines and the promise of phase 3 clinical trials: anti-obesity drugs in the sky and on the horizon.J Obes Metab Syndr. 2023;32(2):106-120.
140. Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.EClinicalMedicine. 2023;58:101882.
141. Jamaluddin A, Gorvin CM. RISING STARS: targeting G protein-coupled receptors to regulate energy homeostasis.J Mol Endocrinol. 2023;70(4):e230014.
142. Santamaría A, Arias HR. Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats.Behav Brain Res. 2010;211(1):132-139.
143. Lucchetta RC, Riveros BS, Pontarolo R, et al. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.Clinics (Sao Paulo). 2017;72(5):317-324.
144. Suplicy H, Boguszewski CL, dos Santos CMC, do Desterro de Figueiredo M, Cunha DR, Radominski R. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.Int J Obes (Lond). 2014;38(8):1097-1103.
145. Soto-Molina H, Pizarro-Castellanos M, Rosado-Pérez J, et al. Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial.Int J Clin Pharmacol Ther. 2015;53(7):541-549.
146. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review.JAMA. 2014;311(1):74-86.
147. Jastreboff AM, Kushner RF. New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics.Annu Rev Med. 2023;74:125-139.
148. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.Am J Clin Nutr. 2012;95(2):297-308.
149. Lei XG, Ruan JQ, Lai C, Sun Z, Yang X. Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: a systematic review and meta-analysis.Obesity (Silver Spring). 2021;29(6):985-994.
150. Gjermeni E, Kirstein AS, Kolbig F, et al. Obesity: an update on the basic pathophysiology and review of recent therapeutic advances.Biomolecules. 2021;11(10):1426.
151. Guglielmi V, Bettini S, Sbraccia P, et al. Beyond weight loss: added benefits could guide the choice of anti-obesity medications.Curr Obes Rep. 2023;12(2):127-146.
152. Sodhi M, Rezaeianzadeh R, Kezouh A, et al. Research letter: risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss.JAMA. 2023;330(18):1795-1797.
153. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2023;402(10403):705-719.
154. He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials.JAMA Intern Med. 2022;182(5):513-519.
155. U.S. Food and Drug Administration. Press Release: FDA Approves New Medication for Chronic Weight Management. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management. Last accessed November 15, 2023.
156. Bailey CJ, Flatt PR, Conlon JM. An update on peptide-based therapies for type 2 diabetes and obesity.Peptides. 2023;161:170939.
157. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet. 2023;402(10402):613-626.
158. le Roux CW, Hankosky ER, Wang D, et al. Tirzepatide 10 and 15mg compared with semaglutide 2.4mg for the treatment of obesity: an indirect treatment comparison.Diabetes Obes Metab. 2023;25(9):2626-2633.
159. Tan B, Pan XH, Chew HSJ, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.Int J Obes (Lond). 2023;47(8):677-685.
160. Patoulias D, Caprio M, Stoian AP, Rizzo M. Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!Expert Opin Drug Saf. 2023;22(9):763-765.
161. Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.Nat Med. 2022;28(3):591-598.
162. Arunachalam A, Nguyen A, Shah NL. THU255 Tirzepatide-induced weight loss in a type 2 diabetic taking oral contraceptives.J Endocr Soc. 2023;7(Suppl 1):bvad114.692.
163. D'Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: a long-acting amylin analog for the treatment of obesity.Cardiol Rev. 2023.
164. 164. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet. 2023;402(10403):720-730.
165. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial.N Engl J Med. 2023;389(6):514-526.
166. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet. 2023;402(10401):529-544.
167. Jungnik A, Martinez JA, Plum-Mörschel L, et al. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.Diabetes Obes Metab. 2023;25(4):1011-1023.
168. Yazawa R, Ishida M, Balavarca Y, Hennige AM. A randomized phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.Diabetes Obes Metab. 2023;25(7):1973-1984.
169. Heymsfield SB, Coleman LA, Miller R, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial.JAMA Netw Open. 2021;4(1):e2033457.
170. Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity.N Engl J Med. 2023;389(10):877-888.
171. Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.Diabetes Obes Metab. 2023;25(9):2642-2649.
172. Saxena AR, Frias JP, Brown LS, et al. Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial.JAMA Netw Open. 2023;6(5):e2314493.
173. Saxena AR, Frias JP, Gorman DN, et al. Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, phase 2 study comparing different dose-escalation schemes.Diabetes Obes Metab. 2023;25(10):2805-2814.
174. Cision PR Newswire. Press Release: Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism. Available at https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-publication-of-discovery-preclinical-and-phase-1-clinical-trial-results-of-ecnoglutide-xw003-in-molecular-metabolism-301873994.html. Last accessed November 15, 2023.
175. Zhu Z, Li Y, Zheng Q, et al. 79-LB: an open-label, active-controlled phase 2 evaluation of novel GLP-1 analog ecnoglutide in adults with obesity. Diabetes. 2023;72(Supplement_1):79-LB.
176. ClinicalTrials.gov. A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults with Overweight or Obesity. Available at https://classic.clinicaltrials.gov/ct2/show/NCT05813795. Last accessed November 10, 2023.
177. Cision PR Newswire. Press Release: Innovent Announces Phase 2 Clinical Study of Higher Dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint. Available at https://www.prnewswire.com/news-releases/innovent-announces-phase-2-clinical-study-of-higher-dose-9-mg-mazdutide-ibi362-in-chinese-adults-with-obesity-achieved-the-24-week-primary-endpoint-301821038.html. Last accessed November 14, 2023.
178. Gerhard D. Targeting Nutrient Signaling in the Gut to Tackle Metabolic Disease. May 11, 2023. Available at https://www.drugdiscoverynews.com/targeting-nutrient-signaling-in-the-gut-to-tackle-metabolic-disease-15669. Last accessed November 10, 2023.
179. ClinicalTrials.gov. A Study of Distal Jejunal-Release Dextrose in Obese Participants. Available at https://clinicaltrials.gov/ct2/show/NCT05385978. Last accessed November 10, 2023.
180. Bariatric News. Three Trials to Assess ARD-101 Including for Refractory Weight Gain Post-Bariatric Surgery. Available at https://www.bariatricnews.net/post/three-trials-to-assess-ard-101-including-for-refractory-weight-gain-post-bariatric-surgery. Last accessed November 10, 2023.
181. Cision PR Newswire. Press Release: Aardvark Therapeutics Reports Positive Phase II Clinical Data for ARD-101. Available at https://www.prnewswire.com/news-releases/aardvark-therapeutics-reports-positive-phase-ii-clinical-data-for-ard-101-301848268.html. Last accessed November 14, 2023.
182. Mishra S, Sadagopan N, Dunkerly-Eyring B, et al. Inhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice. J Clin Invest. 2021;131(21):e148798.
183. ClinicalTrials.gov. Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Obese Subjects with Type 2 Diabetes at Risk of Nonalcoholic Steatohepatitis. Available at https://www.clinicaltrials.gov/study/NCT05979779. Last accessed November 10, 2023.
184. Murphy T, Le Foll B. Targeting the endocannabinoid CB1 receptor to treat body weight disorders: a preclinical and clinical review of the therapeutic potential of past and present CB1 drugs. Biomolecules. 2020;10(6):855.
185. Le Strat Y, Le Foll B. Obesity and cannabis use: results from 2 representative national surveys. Am J Epidemiol. 2011;174(8):929-933.
186. Giroday G. University of Toronto News: Researcher Explores Use of Cannabinoids to Treat Obesity. Available at https://www.utoronto.ca/news/u-t-researcher-explores-use-cannabinoids-treat-obesity. Last accessed November 13, 2023.
187. Friedrichsen M, Endahl L, Kreiner FF, et al. Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues. medRxiv. 2023;[Epub ahead of print].
188. Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J. 1968;1(5588):352-354.
189. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111-2120.
190. Blum D. What Is Ozempic and Why Is It Getting So Much Attention? Available at https://www.nytimes.com/2022/11/22/well/ozempic-diabetes-weight-loss.html. Last accessed November 10, 2023.
191. Belluz J. What New Weight Loss Drugs Teach Us About Fat and Free Will. Available at https://www.nytimes.com/2023/01/31/opinion/ozempic-weight-loss-drugs.html. Last accessed November 10, 2023.
192. Chiappini S, Vickers-Smith R, Harris D, et al. Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset. Pharmaceuticals (Basel). 2023;16(7):994.
193. Gomez G, Stanford FC. US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity. Int J Obes (Lond). 2018;42(3):495-500.
194. Hendricks EJ. Off-label drugs for weight management. Diabetes Metab Syndr Obes. 2017;10:223-234.
195. San Giovanni CB, Sweeney B, Skelton JA, Kelsey MM, Kelly AS. Aversion to off-label prescribing in clinical pediatric weight management: the quintessential double standard. J Clin Endocrinol Metab. 2021;106(7):2103-2113.
196. Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity (Silver Spring). 2019;27(4):591-602.
197. Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. Int J Obes (Lond). 2014;38(2):292-298.
198. Bays HE, Lazarus E, Primack C, Fitch A. Obesity pillars roundtable: phentermine: past, present, and future. Obes Pillars. 2022;3:100024.
199. Hollander P, Bays HE, Rosenstock J, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care. 2017;40(5):632-639.
200. Albaugh VL, He Y, Münzberg H, Morrison CD, Yu S, Berthoud HR. Regulation of body weight: lessons learned from bariatric surgery. Mol Metab. 2023;68:101517.
201. American Society for Metabolic and Bariatric Surgery. Estimate of Bariatric Surgery Numbers, 2011–2021. June 2022. Available at https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers. Last accessed November 10, 2023.
202. Kermansaravi M, Parmar C, Chiappetta S, et al. Patient selection in one anastomosis/mini gastric bypass: an expert modified Delphi consensus. Obes Surg. 2022;32(8):2512-2524.
203. Lee WJ, Almalki O. Recent advancements in bariatric/metabolic surgery. Ann Gastroenterol Surg. 2017;1(3):171-179.
205. Chierici A, Chevalier N, Iannelli A. Postoperative morbidity and weight loss after revisional bariatric surgery for primary failed restrictive procedure: a systematic review and network meta-analysis. Int J Surg. 2022;102:106677.
206. O'Brien PE, Hindle A, Brennan L, et al. Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding. Obes Surg. 2019;29(1):3-14.
207. Hatoum IJ, Kaplan LM. Advantages of percent weight loss as a method of reporting weight loss after Roux-en-Y gastric bypass. Obesity (Silver Spring). 2013;21(8):1519-1525.
208. Srinivasan M, Thangaraj SR, Arzoun H, Thomas SS, Mohammed L. The impact of bariatric surgery on cardiovascular risk factors and outcomes: a systematic review. Cureus. 2022;14(3):e23340.
209. Widjaja J, Chu Y, Yang J, Wang J, Gu Y. Can we abandon foregut exclusion for an ideal and safe metabolic surgery? Front Endocrinol (Lausanne). 2022;13:1014901.
210. Gulinac M, Miteva DG, Peshevska-Sekulovska M, et al. Long-term effectiveness, outcomes and complications of bariatric surgery. World J Clin Cases. 2023;11(19):4504-4512.
211. Yoshino M, Kayser BD, Yoshino J, et al. Effects of diet versus gastric bypass on metabolic function in diabetes. N Engl J Med. 2020;383(8):721-732.
212. Barthold D, Brouwer E, Barton LJ, et al. Minimum threshold of bariatric surgical weight loss for initial diabetes remission. Diabetes Care. 2022;45(1):92-99.
213. Steffen R, Horber FF. Surgical prevention of weight regain and type 2 diabetes recurrence in 3 different bariatric operations and their differential long-term outcome: an 8-year prospective observational study. Ann Surg Open. 2021;2(2):e053.
214. Axer S, Lederhuber H, Stiede F, Szabo E, Näslund I. Weight-related outcomes after revisional bariatric surgery in patients with non-response after sleeve gastrectomy-a systematic review. Obes Surg. 2023;33(7):2210-2218.
215. Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879-887.
216. Pereira SS, Guimarães M, Monteiro MP. Towards precision medicine in bariatric surgery prescription. Rev Endocr Metab Disord. 2023;24(5):961-977.
217. Courcoulas AP, Christian NJ, O'Rourke RW, et al. Preoperative factors and 3-year weight change in the Longitudinal Assessment of Bariatric Surgery (LABS) consortium. Surg Obes Relat Dis. 2015;11(5):1109-1118.
218. Cooiman MI, Alsters SIM, Duquesnoy M, et al. Long-term weight outcome after bariatric surgery in patients with melanocortin-4 receptor gene variants: a case-control study of 105 patients. Obes Surg. 2022;32(3):837-844.
219. Campos A, Cifuentes L, Hashem A, et al. Effects of heterozygous variants in the leptin-melanocortin pathway on Roux-en-Y gastric bypass outcomes: a 15-year case-control study. Obes Surg. 2022;32(8):2632-2640.
220. Flanagan E, Ghaderi I, Overby DW, Farrell TM. Reduced survival in bariatric surgery candidates delayed or denied by lack of insurance approval. Am Surg. 2016;82(2):166-170.
221. Gunnarson GL, Frøyen JK, Sandbu R, Thomsen JB, Hjelmesæth J. Plastic surgery after bariatric surgery.Tidsskr Nor Laegeforen. 2015;135(11):1044-1049.
222. Froylich D, Corcelles R, Daigle CR, et al. Weight loss is higher among patients who undergo body contouring procedures after bariatric surgery.Surg Obes Relat Dis. 2016;12(9):1731-1736.
223. El Abd R, Samargandi OA, Al Ghanim K, et al. Body contouring surgery improves weight loss after bariatric surgery: a systematic review and meta-analysis.Aesthetic Plast Surg. 2021;45(3):1064-1075.
224. Noria SF, Shelby RD, Atkins KD, Nguyen NT, Gadde KM. Weight regain after bariatric surgery: scope of the problem, causes, prevention, and treatment.Curr Diab Rep. 2023;23(3):31-42.
225. van de Laar AW, van Rijswijk AS, Kakar H, Bruin SC. Sensitivity and specificity of 50% excess weight loss (50%EWL) and twelve other bariatric criteria for weight loss success.Obes Surg. 2018;28(8):2297-2304.
226. McClelland PH, Jawed M, Kabata K, Zenilman ME, Gorecki P. Long-term outcomes following laparoscopic Roux-en-Y gastric bypass: weight loss and resolution of comorbidities at 15 years and beyond.Surg Endosc. 2023.
227. Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS Randomized Clinical Trial.JAMA. 2018;319(3):255-265.
228. Wei Y, Li P, Zhang S. From surgery to endoscopy: the evolution of the bariatric discipline.Chin Med J (Engl). 2022;135(20):2427-2435.
229. Adams TD, Davidson LE, Litwin SE, et al. Weight and metabolic outcomes 12 years after gastric bypass.N Engl J Med. 2017;377(12):1143-1155.
230. Vitiello A, Abu-Abeid A, Dayan D, Berardi G, Musella M. Long-term results of laparoscopic sleeve gastrectomy: a review of studies reporting 10+ years outcomes.Obes Surg. 2023;33(11):3565-3570.
231. Salminen P, Grönroos S, Helmiö M, et al. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity.JAMA Surg. 2022;157(8):656-666.
232. Lucido FS, Scognamiglio G, Nesta G, et al. It is really time to retire laparoscopic gastric banding? Positive outcomes after long-term follow-up: the management is the key.Updates Surg. 2022;74(2):715-726.
233. Benson-Davies S, Rogers AM, Huberman W, et al. American Society of Metabolic and Bariatric Surgery consensus statement on laparoscopic adjustable gastric band management.Surg Obes Relat Dis. 2022;18(9):1120-1133.
234. Kallies K, Rogers AM, American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. American Society for Metabolic and Bariatric Surgery updated statement on single-anastomosis duodenal switch.Surg Obes Relat Dis. 2020;16(7):825-830.
235. Pennestrì F, Sessa L, Prioli F, et al. Single anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S): experience from a high-bariatric volume center.Langenbecks Arch Surg. 2022;407(5):1851-1862.
236. Spinos D, Skarentzos K, Esagian SM, Seymour KA, Economopoulus KP. The effectiveness of single-anastomosis duodenoileal bypass with sleeve gastrectomy/one anastomosis duodenal switch (SADI-S/OADS): an updated systematic review.Obes Surg. 2021;31(4):1790-1800.
237. Carbajo MA, Luque-de-León E, Jiménez JM, Ortiz-de-Solórzano J, Pérez-Miranda M, Castro-Alija MJ. Laparoscopic one-anastomosis gastric bypass: technique, results, and long-term follow-up in 1200 patients.Obes Surg. 2017;27(5):1153-1167.
238. Shenoy A, Schulman AR. Advances in endobariatrics: past, present, and future.Gastroenterol Rep (Oxf). 2023;11:goad043.
239. Dolan RD, Schulman AR. Endoscopic approaches to obesity management.Annu Rev Med. 2022;73:423-438.
240. Abu Dayyeh BK, Bazerbachi F, Vargas EJ, et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial.Lancet. 2022;400(10350):P441-P451.
241. Fehervari M, Fadel MG, Alghazawi LOK, et al. Medium-term weight loss and remission of comorbidities following endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Obes Surg. 2023;33(11):3527-3538.
242. Brunaldi VO, Neto MG, Sharaiha RZ, et al. Endoscopic sleeve gastroplasty as an early tool against obesity: a multicenter international study on an overweight population. Gastrointest Endosc. 2023;S0016-S5107(23)02973-5.
243. Singh S, Bazarbashi AN, Khan A, et al. Primary obesity surgery endoluminal (POSE) for the treatment of obesity: a systematic review and meta-analysis. Surg Endosc. 2022;36(1):252-266.
244. Abdelgawad M, Elgeidie A, Sorogy ME, Elrefai M, Hamed H, El-Magd EA. Long-term outcomes of laparoscopic gastric plication for treatment of morbid obesity: a single-center experience. Obes Surg. 2022;32(10):3324-3331.
245. The Medical Letter. Drugs and devices for weight management. Med Lett Drugs Ther. 2022;64(1651):81-88.
246. Moore RL, Seger MV, Garber SM, et al. Clinical safety and effectiveness of a swallowable gas-filled intragastric balloon system for weight loss: consecutively treated patients in the initial year of U.S. commercialization. Surg Obes Relat Dis. 2019;15(3):417-423.
247. Dave N, Dawod E, Simmons OL. Endobariatrics: a still underutilized weight loss tool. Curr Treat Options Gastroenterol. 2023;21(2):172-184.
248. Apovian CM, Shah SN, Wolfe BM, et al. Two-year outcomes of vagal nerve blocking (vBloc) for the treatment of obesity in the ReCharge trial. Obes Surg. 2017;27(1):169-176.
249. Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA. 2021;326(20):2031-2042.
250. Carlsson LMS, Sjöholm K, Jacobson P, et al. Life expectancy after bariatric surgery in the Swedish Obese Subjects study. N Engl J Med. 2020;383(16):1535-1543.
251. Syn NL, Cummings DE, Wang LZ, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet. 2021;397(10287):1830-1841.
252. Carlsson LMS, Carlsson B, Jacobson P, et al. Life expectancy after bariatric surgery or usual care in patients with or without baseline type 2 diabetes in Swedish obese subjects. Int J Obes (Lond). 2023;47(10):931-938.
253. Lind R, Hage K, Ghanem M, et al. Long-term outcomes of sleeve gastrectomy: weight recurrence and surgical non-responders. Obes Surg. 2023;33(10):3028-3034.
254. Jensen AB, Renström F, Aczél S, et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33(4):1017-1025.
255. Dang JT, Kim GJ, Kroh M. Bariatric endoscopy: from managing complications to primary metabolic procedures. J Minim Invasive Surg. 2023;26(1):1-8.
256. Mok J, Adeleke MO, Brown A, et al. Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE Randomized Clinical Trial. JAMA Surg. 2023;158(10):1003-1011.
257. Horber FF, Steffen R. Reversal of long-term weight regain after Roux-en-Y gastric bypass using liraglutide or surgical revision. A prospective study. Obes Surg. 2021;31(1):93-100.
258. Murvelashvili N, Xie L, Schellinger JN, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity (Silver Spring). 2023;31(5):1280-1289.
259. Redmond IP, Shukla AP, Aronne LJ. Use of weight loss medications in patients after bariatric surgery. Curr Obes Rep. 2021;10(2):81-89.
260. Badurdeen D, Hoff AC, Hedjoudje A, et al. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointest Endosc. 2021;93(6):1316-1324.e1.
261. Clapp B, Harper B, Dodoo C, et al. Trends in revisional bariatric surgery using the MBSAQIP database 2015-2017. Surg Obes Relat Dis. 2020;16(7):908-915.
262. Clapp B, Wynn M, Martyn C, Foster C, O'Dell M, Tyroch A. Long term (7 or more years) outcomes of the sleeve gastrectomy: a meta-analysis. Surg Obes Relat Dis. 2018;14(6):741-747.
263. Del Gobbo GD, Mahmoud N, Barajas-Gamboa JS, et al. Conversion of sleeve gastrectomy to Roux-en-Y gastric bypass to enhance weight loss: single enterprise mid-term outcomes and literature review. Bariatr Surg Pract Patient Care. 2022;17(4):197-205.
264. Salama AF, Baazaoui J, Shahid F, Singh R, Torres AJ, Bashah MM. Comparative analysis of 5-year efficacy and outcomes of single anastomosis procedures as revisional surgery for weight regain following sleeve gastrectomy. Surg Endosc. 2023;37(10):7548-7555.
265. Parmar CD, Gan J, Stier C, et al. One anastomosis/mini gastric bypass (OAGB-MGB) as revisional bariatric surgery after failed primary adjustable gastric band (LAGB) and sleeve gastrectomy (SG): a systematic review of 1075 patients. Int J Surg. 2020;81:32-38.
266. Jais A, Brüning JC. Arcuate nucleus-dependent regulation of metabolism—pathways to obesity and diabetes mellitus. Endocr Rev. 2022;43(2):314-328.
267. Roh E, Choi KM. Hormonal gut-brain signaling for the treatment of obesity. Int J Mol Sci. 2023;24(4):3384.
268. Timper K, Brüning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis Model Mech. 2017;10(6):679-689.
269. Lieu L, Chau D, Afrin S, et al. Effects of metabolic state on the regulation of melanocortin circuits. Physiol Behav. 2020;224:113039.
270. Li H, Xu Y, Jiang Y, et al. The melanocortin action is biased toward protection from weight loss in mice. Nature communications. 2023;14:2200.
271. Yeo GSH, Chao DHM, Siegert AM, et al. The melanocortin pathway and energy homeostasis: from discovery to obesity therapy. Mol Metab. 2021;48:101206.
272. Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120-133.
273. Rossi MA, Stuber GD. Overlapping brain circuits for homeostatic and hedonic feeding. Cell Metab. 2018;27(1):42-56.
274. Garfield AS, Li C, Madara JC, et al. A neural basis for melanocortin-4 receptor-regulated appetite. Nat Neurosci. 2015;18(6):863-871.
275. Zagmutt S, Mera P, Soler-Vázquez MC, Herrero L, Serra D. Targeting AgRP neurons to maintain energy balance: lessons from animal models. Biochem Pharmacol. 2018;155:224-232.
276. Puente-Ruiz SC, Jais A. Reciprocal signaling between adipose tissue depots and the central nervous system. Front Cell Dev Biol. 2022;10:979251.
277. Deem JD, Faber CL, Morton GJ. AgRP neurons: regulators of feeding, energy expenditure, and behavior. FEBS J. 2022;289(8):2362-2381.
278. Hollstein T, Piaggi P. Metabolic factors determining the susceptibility to weight gain: current evidence. Curr Obes Rep. 2020;9(2):121-135.
279. Guilherme A, Henriques F, Bedard AH, Czech MP. Molecular pathways linking adipose innervation to insulin sensitivity in obesity and type 2 diabetes. Nat Rev Endocrinol. 2019;15(4):207-225.
280. Koch M, Varela L, Kim JG, et al. Hypothalamic POMC neurons promote cannabinoid-induced feeding. Nature. 2015;519(7541):45-50.
281. Myers MG Jr, Affinati AH, Richardson N, Schwartz MW. Publisher correction: central nervous system regulation of organismal energy and glucose homeostasis.Nat Metab. 2021;3(7):1033.
282. Szalanczy AM, Key CCC, Woods LCS.Genetic variation in satiety signaling and hypothalamic inflammation: merging fields for the study of obesity.J Nutr Biochem. 2022;101:108928.
283. Wachsmuth HR, Weninger SN, Duca FA. Role of the gut-brain axis in energy and glucose metabolism.Exp Mol Med. 2022;54(4):377-392.
284. Del Prato S, Gallwitz B, Holst JJ, Meier JJ. The incretin/glucagon system as a target for pharmacotherapy of obesity.Obes Rev. 2022;23(2):e13372.
285. Savova MS, Mihaylova LV, Tews D, Wabitsch M, Georgiev MI. Targeting PI3K/AKT signaling pathway in obesity.Biomed Pharmacother. 2023;159:114244.
286. de Boleti AP, de O Cardoso PH, Frihling BEF, Silva PSE, de Moraes LFRN, Migliolo L. Adipose tissue, systematic inflammation, and neurodegenerative diseases.Neural Regen Res. 2023;18(1):38-46.
287. Jin X, Qiu T, Li L, et al. Pathophysiology of obesity and its associated diseases.Acta Pharm Sin B.2023;13(6):2403-2424.
288. Richard AJ, White U, Elks CM, Stephens JM. Adipose tissue: physiology to metabolic dysfunction. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds).Endotext. South Dartmouth, MA: MDText.com, Inc.; 2020.
289. Attia P. Narrative Glossary. Available at https://peterattiamd.com/narrative-glossary. Last accessed November 10, 2023.
290. Feingold KR. Role of glucose and lipids in the atherosclerotic cardiovascular disease of patients with diabetes. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds).Endotext. South Dartmouth, MA: MDText.com, Inc.; 2020.
291. Brondeel KC, Lakatta AC, Torres GB, et al. Physiologic and pharmacologic considerations in morbid obesity and bariatric anesthesia.Saudi J Anaesth. 2022;16(3):306-313.
292. Heindel JJ, Blumberg B, Cave M, et al. Metabolism disrupting chemicals and metabolic disorders.Reprod Toxicol. 2017;68:3-33.
293. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox.Cell Metab. 2008;7(2):95-96.
294. Askarpour M, Alizadeh S, Hadi A, et al. Effect of bariatric surgery on the circulating level of adiponectin, chemerin, plasminogen activator inhibitor-1, leptin, resistin, and visfatin: a systematic review and meta-analysis.Horm Metab Res. 2020;52(4):207-215.
295. Keshavjee SH, Schwenger KJP, Yadav J, Jackson TD, Okrainec A, Allard JP. Factors affecting metabolic outcomes post bariatric surgery: role of adipose tissue.J Clin Med. 2021;10(4):714.
296. Kirichenko TV, Markina YV, Bogatyreva AI, Tolstik TV, Varaeva YR, Starodubova AV. The role of adipokines in inflammatory mechanisms of obesity.Int J Mol Sci. 2022;23(23):14982.
297. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity.Am J Physiol Cell Physiol. 2021;320(3):C375-C391.
298. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease.J Cardiol. 2014;63(4):250-259.
299. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders.Immunity. 2022;55(1):31-55.
300. Perdomo CM, Avilés-Olmos I, Dicker D, Frühbeck G. Towards an adiposity-related disease framework for the diagnosis and management of obesities.Rev Endocr Metab Disord. 2023;24(5):795-807.
301. Powers AC, D'Alessio D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: Brunton LL, Hilal-Dandan R, Knollmann BC (eds).Goodman and Gilma''s: The Pharmacological Basis of Therapeutics.13th ed. New York, NY: McGraw Hill; 2017.
302. Kyrou I, Randeva HS, Tsigos C, Kaltsas G, Weickert MO. Clinical problems caused by obesity. In: Feingold KR, Anawalt B, Blackman MR, et al. (eds).Endotext. South Dartmouth, MA: MDText.com, Inc.; 2018.
303. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus.Nat Rev Dis Primers. 2015;1:15019.
304. Freeman AM, Acevedo LA, Pennings N. Insulin resistance.StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
305. Haskins IN, Chang J, Hanipah ZN, et al. Patients with clinically metabolically healthy obesity are not necessarily healthy subclinically: further support for bariatric surgery in patients without metabolic disease?Surg Obes Relat Dis. 2018;14(3):342-346.
306. Goyal R, Singhal M, Jialal I. Type 2 diabetes.StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
307. Mathis BJ, Tanaka K, Hiramatsu Y. Metabolically healthy obesity: are interventions useful?Curr Obes Rep. 2023;12(1):36-60.
308. Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90,257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study.Lancet Diabetes Endocrinol. 2018;6(9):714-724.
309. Mishra M, Erman M. Pfizer Drops Twice-Daily Version of Obesity Pill Over Side Effects. Available at https://www.medscape.com/s/viewarticle/998973. Last accessed December 11, 2023.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.